By Ian Walker

LONDON--Pharmaceutical company AstraZeneca PLC (AZN.LN) said Thursday that the European Medicines Agency has approved its marketing application for Lesinurad, a treatment for gout.

The authorization means AstraZeneca can begin to promote the medicine within the European Union, as well as in the European Economic Area countries Iceland, Liechtenstein and Norway.

Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more AstraZeneca Charts.